The Predictive Role of Skin Rash with Cetuximab and Panitumumab in Colorectal Cancer Patients: a Systematic Review and Meta-analysis of Published Trials

Overview

Journal Target Oncol

Specialty Oncology

Date 2013 Jan 17

PMID 23321777

Citations 52

Authors

F Petrelli

K Borgonovo

S Barni

Affiliations

Soon will be listed here.

Abstract

Skin rash is an early and frequent phenomenon during treatment with anti-epidermal growth factor receptor monoclonal antibodies. The objective of this review is to assess the predictive value of skin rash in patients with advanced colorectal cancer treated with cetuximab and panitumumab. We searched PubMed and ASCO Meetings for publications reporting the correlation of skin rash with survival and/or response rate. Hazard ratios (HRs) with 95% confidence intervals for progression and/or survival, and/or risk ratios (RRs) for response rate in patients with rash were obtained from publications and pooled in a meta-analysis. Fourteen publications (for a total of 3,833 patients) were included in this meta-analysis. The occurrence of skin toxicity represents a predictive factor for survival (HR 0.51; p<0.00001) and progression (HR 0.58; p<0.00001). Similarly, patients who developed moderate or severe rash had an increased chance of response (35 vs 13%; RR 2.23, p<0.00001). The occurrence of skin rash during treatment with cetuximab and panitumumab represents a significant predictor of the efficacy of these drugs. The hypothesis that, in patients who lack substantial skin toxicity, this treatment is not beneficial and requires early discontinuation deserves further study.

Citing Articles

Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

Trembath H, Yeh J, Lopez N Cancer Treat Res. 2024; 192:305-418.

PMID: 39212927 DOI: 10.1007/978-3-031-61238-1_15.

Panitumumab-Induced Periorbital Dermatitis: A Case Report.

Pongbangpho N, Chanprapaph K, Iamsumang W Clin Cosmet Investig Dermatol. 2024; 17:763-767.

PMID: 38586180 PMC: 10999196. DOI: 10.2147/CCID.S459067.

The Effect of Topical Vitamin K1 on the Treatment of Cetuximab-Induced Skin Rashes in Metastatic Colorectal Cancer Patients.

Roayaei M, Rezaei M, Najafizade N Adv Biomed Res. 2024; 12:260.

PMID: 38192897 PMC: 10772800. DOI: 10.4103/abr.abr_141_23.

An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.

Bierbrier R, DAguanno K, Oliel S, Zeng Y, Esfahani K, Pehr K J Cutan Med Surg. 2023; 27(6):614-620.

PMID: 37942582 PMC: 10714707. DOI: 10.1177/12034754231211326.

Colon Cancer Pharmacogenetics: A Narrative Review.

Alfaro Alfaro A, Murillo Castillo B, Cordero Garcia E, Tascon J, Morales A Pharmacy (Basel). 2022; 10(4).

PMID: 36005935 PMC: 9413567. DOI: 10.3390/pharmacy10040095.

References

Lacouture M . Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6(10):803-12. DOI: 10.1038/nrc1970. View

Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R . Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer. 2008; 7(1):48-54. DOI: 10.3816/CCC.2008.n.007. View

Van Cutsem E, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14):1408-17. DOI: 10.1056/NEJMoa0805019. View

Paez D, Pare L, Espinosa I, Salazar J, del Rio E, Barnadas A . Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?. Cancer Sci. 2010; 101(9):2048-53. PMC: 11158139. DOI: 10.1111/j.1349-7006.2010.01621.x. View

Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H . Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol. 2012; 30(23):2861-8. DOI: 10.1200/JCO.2011.40.9243. View

Levi F, Karaboue A, Gorden L, Innominato P, Saffroy R, Giacchetti S . Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2010; 67(2):339-48. DOI: 10.1007/s00280-010-1327-8. View

Burtness B, Anadkat M, Basti S, Hughes M, Lacouture M, McClure J . NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw. 2009; 7 Suppl 1:S5-21. DOI: 10.6004/jnccn.2009.0074. View

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S . Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2011; 26(7):823-33. DOI: 10.1007/s00384-011-1149-0. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

10.

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

11.

Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10):1626-34. DOI: 10.1200/JCO.2007.14.7116. View

12.

Jonker D, OCallaghan C, Karapetis C, Zalcberg J, Tu D, Au H . Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357(20):2040-8. DOI: 10.1056/NEJMoa071834. View

13.

Gamucci T, Nelli F, Cianci G, Grassi G, Moscetti L, Sperduti I . A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clin Colorectal Cancer. 2008; 7(4):273-9. DOI: 10.3816/CCC.2008.n.035. View

14.

Lenz H, Van Cutsem E, Khambata-Ford S, Mayer R, Gold P, Stella P . Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006; 24(30):4914-21. DOI: 10.1200/JCO.2006.06.7595. View

15.

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13):1658-64. DOI: 10.1200/JCO.2006.08.1620. View

16.

Stintzing S, Kapaun C, Laubender R, Jung A, Neumann J, Modest D . Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO.... Int J Cancer. 2012; 132(1):236-45. DOI: 10.1002/ijc.27654. View

17.

Park J, Han S, Oh D, Im S, Jeong S, Park K . Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol. 2011; 68(4):1045-55. DOI: 10.1007/s00280-011-1586-z. View

18.

Lacouture M, Anadkat M, Bensadoun R, Bryce J, Chan A, Epstein J . Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19(8):1079-95. PMC: 3128700. DOI: 10.1007/s00520-011-1197-6. View

19.

Jehn C, Boning L, Kroning H, Possinger K, Luftner D . Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012; 106(2):274-8. PMC: 3261677. DOI: 10.1038/bjc.2011.554. View

20.

Pinto C, Barone C, Girolomoni G, Russi E, Merlano M, Ferrari D . Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011; 16(2):228-38. PMC: 3228080. DOI: 10.1634/theoncologist.2010-0298. View